(SGRY) Surgery Partners, Inc. Company Overview

Surgery Partners, Inc. is a Nasdaq-listed healthcare-services company operating under ticker SGRY. It owns, operates, and manages a national network of ambulatory surgery centers, or ASCs, surgical hospitals, physician practices, anesthesia operations, urgent-care locations, and related ancillary services. The core proposition is short-stay, mostly non-emergency care delivered outside a full-service acute-care hospital. According to the company’s first-quarter 2026 Form 10-Q, the portfolio comprised 180 facilities, including 161 ASCs and 19 surgical hospitals.

Why is the outpatient model strategically important?

Focused facilities can perform many scheduled procedures with lower overhead and simpler scheduling than general hospitals. Surgery Partners concentrates on orthopedics and pain management, gastroenterology, ophthalmology, and general surgery. These specialties combine recurring demand with opportunities to move more complex procedures outpatient as clinical techniques, reimbursement, and technology evolve.

Consolidated facilities earn patient-service revenue by charging for operating and recovery rooms, nursing, medications, supplies, and equipment; attending physicians generally bill professional fees separately. Surgery Partners also earns management fees from non-consolidated facilities and practices. In FY2025, patient-service revenue represented 97.5% of total revenue and other services 2.5%, according to the 2025 Form 10-K.

Who pays, and why does payor mix matter?

Private insurers and government programs determine much of the realized price. The company negotiates commercial contracts, while Medicare and Medicaid reimbursement is governed by regulation. A richer commercial mix can support revenue per case, but government programs provide meaningful volume and expose the business to policy changes. In the first quarter of 2026, private insurance represented 50.4% of patient-service revenue, government payors 45.1%, self-pay 2.4%, and other payors 2.1%.

How does the partnership structure change reported economics?

Surgery Partners often co-owns facilities with physicians and health systems. At March 31, 2026, it held a majority interest in 89 facilities and consolidated 122 for financial reporting. Partners receive distributions and a share of earnings through non-controlling interests. This structure is strategically useful because physician ownership can align referral behavior, clinical commitment, and growth incentives, but it also means consolidated operating income does not fully accrue to common shareholders.

Surgery Partners reports one operating segment, Surgical Facilities, making case mix more informative than segment revenue. Higher-acuity musculoskeletal procedures generally produce more revenue per case, so management is shifting toward orthopedics, spine, total joints, and other procedures that can migrate from hospitals into short-stay facilities.

Why is musculoskeletal growth central?

Orthopedics and pain management increased from 36.1% of consolidated cases in FY2023 to 40.7% in FY2025. Complex orthopedic and total-joint procedures can raise revenue per case and justify specialized equipment, but they also demand skilled staffing and disciplined room utilization. The company’s FY2025 investor presentation highlighted roughly 270,000 musculoskeletal procedures, 19% year-over-year total-joint growth, and 74 surgical robots.

What geographic concentration deserves attention?

The network is national, yet the economics are not evenly distributed. The 2025 Form 10-K states that Idaho represented approximately 28% of FY2025 revenue through three consolidated surgical hospitals and four consolidated ASCs. That concentration can magnify the effect of state reimbursement programs, local labor availability, physician relationships, and regulatory changes. National scale is an advantage, but a material share of revenue remains exposed to a small number of local operating ecosystems.

The latest official package is the quarter ended March 31, 2026. Revenue rose because same-facility revenue increased 4.4%, driven by a 3.8% increase in revenue per case and a 0.6% increase in same-facility cases. The company’s first-quarter 2026 earnings release reaffirmed full-year guidance of $3.35 billion to $3.45 billion of revenue and at least $530 million of adjusted EBITDA.

Why did EBITDA lag revenue?

Adjusted EBITDA fell from $103.9 million in Q1 2025 to $102.3 million in Q1 2026 despite revenue growth. Cost of revenue rose faster than sales, and management cited the expense of higher-acuity procedures and state supplemental-program provider taxes. This is the central near-term tension: the case mix that can create stronger long-run revenue per case can also require more implants, supplies, staff, and capital before operating leverage appears.

The company’s history is a sequence of acquisitions, ownership transitions, and operating-model refinement. Its official company history begins in 2004 with a physician-centric model. The events below matter because they created today’s specialty mix, debt load, institutional ownership, and focus on short-stay care.

1. 2004
   Formation. Surgery Partners begins with ASCs, physician practices, and anesthesia services, establishing the partnership model that still underpins physician alignment.
2. 2011
   NovaMed merger. The transaction expands ophthalmology capabilities and ancillary reach, creating a broader multi-specialty network.
3. 2014
   Symbion acquisition. Scale increases materially, adding surgical facilities and experienced operating teams.
4. 2015
   Initial public offering. The Nasdaq listing creates public equity access but also exposes the company’s leverage, acquisition returns, and minority-interest economics to market scrutiny.
5. 2017
   National Surgical Healthcare acquisition and Bain investment. The approximately $760 million transaction adds orthopedic, spine, pain, and neurosurgical assets; Bain becomes the dominant shareholder. The official transaction announcement explains the strategic combination.
6. 2020
   Eric Evans becomes CEO. The strategy increasingly emphasizes organic performance, higher-acuity procedures, physician recruitment, and portfolio quality.
7. 2025–26
   Strategic tension becomes visible. Bain proposes to acquire the remaining shares in January 2025; by early 2026 the public company instead announces a $200 million repurchase authorization while emphasizing leverage reduction and operating improvement.

Physician alignment is the core strategic resource

The company does not simply rent operating rooms. It forms joint ventures, recruits physicians, supplies capital and technology, negotiates contracts, and manages compliance and operations. Physician investors can benefit economically when a facility grows, giving Surgery Partners a relationship-based advantage that is difficult to reproduce quickly. The limitation is that most physicians are not employees and are not contractually required to use the company’s facilities, so the moat depends on service quality and local trust rather than absolute control.

Who are the main competitors?

Competition is local and national. Surgery Partners names HCA Healthcare, AMSURG, Tenet Healthcare, and Optum among large operators, while local hospitals, health systems, physician-owned centers, and office-based procedure settings compete for cases and clinicians. The company’s edge is a focused independent platform, but larger integrated systems may have stronger balance sheets, broader referral networks, and more bargaining power with payors.

The business generates EBITDA and operating cash flow, but interest expense and non-controlling interests constrain common-shareholder earnings. FY2025 revenue was $3.309 billion, adjusted EBITDA $526.2 million, operating income $389.5 million, and operating cash flow $274.3 million. Net loss attributable to Surgery Partners was $77.9 million after $272.6 million of net interest expense and $176.8 million of earnings attributable to non-controlling interests.

Debt and liquidity are the binding constraints

How good is cash-flow conversion?

FY2025 operating cash flow of $274.3 million less $78.7 million of capital spending implies about $195.6 million of simple free cash flow before acquisitions, partner distributions, and financing. However, the company paid $162.1 million for acquisitions and distributed $179.5 million to non-redeemable partners. A conventional free-cash-flow figure therefore overstates cash available to common shareholders unless those outflows are modeled separately.

Surgery Partners has one class of common stock with one vote per share, but ownership is not dispersed in the usual sense. Bain Capital Investors beneficially owned 49.95 million shares, or 38.2%, as of March 31, 2026. The latest 2026 proxy statement also disclosed Janus Henderson at 10.0%, Pentwater Capital at 7.6%, King Street Capital at 7.1%, Vanguard at 5.7%, and FMR at 5.0%.

What does the Bain relationship signal?

Bain’s influence dates to the 2017 National Surgical Healthcare transaction. In January 2025, Bain proposed buying the remaining shares for $25.75 each, which the company acknowledged in an official announcement. The analytical point is that a large sponsor holder can materially influence board composition, strategic alternatives, financing, and capital allocation.

How are executives incentivized?

The 2025 annual incentive framework weighted adjusted EBITDA at 70%, net revenue at 15%, and cash flow at 15%. Revenue exceeded threshold but stayed below target, while EBITDA and cash flow were below threshold; no annual cash incentive was paid. The design shows that compensation depended on operating scale and cash conversion, not revenue alone.

The growth opportunity is structurally attractive but operationally demanding

The long-run opportunity is migration from inpatient hospitals to outpatient sites, supported by demographics, patient preference, payor interest in lower-cost care, and technology. Surgery Partners estimates that roughly $50 billion of inpatient cases could move outpatient within an approximately $150 billion addressable market. Growth can also come from acquisitions, new facilities, service-line expansion, physician recruitment, and higher room utilization.

Which risks are most material?

The 2025 Form 10-K risk factors emphasize reimbursement, payor and case mix, physician retention, clinical labor, supplies, integration, cybersecurity, regulation, and leverage. Federal and state rules govern licensing, physician ownership, referrals, fraud and abuse, privacy, reimbursement, and certificates of need. The joint-venture and acquisition model must remain compliant while offering physicians attractive economics.

A DCF for Surgery Partners should not start with headline revenue alone. The model must separate organic same-facility growth from acquisitions, volume from revenue per case, and consolidated cash flow from cash retained after partner distributions. It should also reflect the company’s debt and lease obligations, because changes in interest cost can materially alter equity value even when facility operations improve.

What should researchers monitor next?